Pfizer Inc. $PFE Shares Sold by Hazlett Burt & Watson Inc.

Hazlett Burt & Watson Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 31.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 10,440 shares of the biopharmaceutical company’s stock after selling 4,798 shares during the quarter. Hazlett Burt & Watson Inc.’s holdings in Pfizer were worth $251,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. CCG Wealth Management LLC increased its position in shares of Pfizer by 47.3% during the 2nd quarter. CCG Wealth Management LLC now owns 11,643 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 3,737 shares during the period. Commonwealth Financial Services LLC raised its position in shares of Pfizer by 12.0% during the second quarter. Commonwealth Financial Services LLC now owns 38,642 shares of the biopharmaceutical company’s stock worth $937,000 after purchasing an additional 4,128 shares during the period. CWM LLC raised its position in shares of Pfizer by 6.0% during the second quarter. CWM LLC now owns 1,488,909 shares of the biopharmaceutical company’s stock worth $36,091,000 after purchasing an additional 84,187 shares during the period. Sippican Capital Advisors raised its position in shares of Pfizer by 37.4% during the second quarter. Sippican Capital Advisors now owns 92,912 shares of the biopharmaceutical company’s stock worth $2,252,000 after purchasing an additional 25,285 shares during the period. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of Pfizer by 26.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 504,446 shares of the biopharmaceutical company’s stock worth $12,230,000 after purchasing an additional 105,453 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PFE shares. Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley cut their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.35.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.72 on Tuesday. The business’s 50-day moving average price is $24.88 and its two-hundred day moving average price is $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82. The company has a market capitalization of $140.52 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.